Use of gamma-aminobutyric acid in preparation of broad-spectrum antiviral drugs for aquaculture
By using γ-aminobutyric acid (GABA) in aquaculture to activate the antiviral immune pathway in shrimp and inhibit the replication of DIV-1 and WSSV, the high mortality rate of shrimp virus infection in existing technologies has been solved, achieving a green and efficient antiviral effect.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- SHANDONG UNIV
- Filing Date
- 2026-06-12
- Publication Date
- 2026-07-17
AI Technical Summary
Current technologies lack effective broad-spectrum antiviral drugs for the prevention and control of Decapoda iridovirus 1 (DIV-1) and white spot syndrome virus (WSSV) infections in shrimp in aquaculture, resulting in high mortality rates and industrial losses. Furthermore, chemical drugs and traditional Chinese medicine products have issues with drug resistance, residues, and quality control, while vaccination faces problems such as limited immunity.
Using γ-aminobutyric acid (GABA) as the active ingredient, a broad-spectrum antiviral drug is prepared by activating the antiviral immune pathway in shrimp through feed addition or intramuscular injection, inhibiting WSSV and DIV-1 genomic mRNA transcription and viral particle replication.
It improves the antiviral ability of shrimp, reduces the mortality rate after viral infection, ensures the healthy development of aquaculture, meets the requirements of green aquaculture, and has no risk of drug residues.
Smart Images
Figure CN122398770A_ABST